Roche bets $700M upfront on Nurix’s late-phase BTK degrader
Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader…
Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg
Roche has entered into a major licensing and collaboration agreement with Nurix Therapeutics for bexobrutideg, an investigational Bruton’s…
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche’s…